In an article by Bul et al published in Eur Urol (2013) the authors conclude that active surveillance is a safe and effective strategy to reduce overtreatment of men with low risk prostate cancer. They studied 2494 men with a PSA <10, Gleason score<7, PSAD<0.2 and less than 3 cores positive. Rebiopsies were scheduled at 1, 4 and 7 years. The treatment was deemed a failure if the PSADT was<3 years or if the was progression on repeat biopsy. At a median follow up of 1.6 years only 28% of patients had progressed.